Daily Policy Digest
|Unpopular Individual Mandate Fails To Make People Buy Obamacare Coverage
The New York Times reports that a number of relatively high-income earners are choosing to remain uninsured, or even drop Obamacare coverage, and pay the fine instead...
|Patients are Becoming Price Sensitive but only Because Obamacare Destroyed Their Insurance
Paying for medical bills out of pocket is a problem because health care providers do not use prices to compete for the patronage of price-sensitive shoppers, writes NCPA Senior Fellow Devon Herrick...
|To Control Drug Prices, Pursue Fraud, Not Manufacturers
There is a better way to control escalating drug costs that by trying to control drug prices...
|Private Health Construction Leads Slow Building Market
In a turnaround from September, private health construction grew strongly, (0.6 percent) while public health construction starts collapsed -2.5 percent...
|Obamacare Beneficiaries' Bleak Future
As more insurers decide to quit, 10 million Obamacare subscribers will be left high and dry in short order, writes NCPA Senior Fellow John R. Graham in the Daily Caller...
|Health Services Spending Growing Faster Than Personal Consumption Expenditures
Obamacare is not bending the cost curve, writes NCPA Senior Fellow John R. Graham...
|Pharmaceutical Marketing, the FDA and Free Speech
The U.S. Justice Department and state attorneys general have repeatedly used the threat of prosecutions for drugmakers touting off-label uses of pharmaceuticals to wring billions of dollars in settlements, fines and civil damages from them.
|What is Driving Health Prices Up?
The recent arrest of Martin Shkreli, former CEO of Turing Pharmaceuticals, for securities fraud, reminds us that high prescription drug prices are today’s whipping boy for the costs of health care...
|Dramatic Drop in Hospital Profitability in 3rd Quarter
The latest Quarterly Services Survey indicates hospitals are finally suffering from an Obamacare hangover. Revenues dropped and margins have shrunk dramatically....
|Trans-Pacific Partnership Deal Undercuts Biologic Innovation
The United States and 11 other Pacific Rim countries recently signed the Trans-Pacific Partnership. Unfortunately, the final draft might not pass Congress because of the deal's inadequate protection of intellectual property in biologic medicines...